Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: A retrospective study

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 278-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1406-1414

John Wiley & Sons Inc

Access to resources Recommend Favorite